Elekta has been awarded its fourth Queen’s Award in as many years. This year, the company is being honored with the Queen’s Award for Innovation 2015. The Queen’s Awards for Enterprise are the UK’s highest accolade for business success. The winners are announced each year on April 21, Her Majesty The Queen’s birthday. The corporate awards recognize outstanding achievements by UK companies in three categories: International Trade, Innovation and Sustainable Development. The award acknowledges Elekta’s 40-year history of developing radiotherapy equipment for the treatment of cancer.
For the second consecutive year, the independent research firm, KLAS, announced that MOSAIQ Oncology Information System earned the number one ranking in the medical and/or radiation oncology category of KLAS’s “Oncology 2014: Integration is Key” report. The survey of 247 customers of various vendors said that “Elekta has improved their MOSAIQ interfaces to take a commanding lead over their competitors.” MOSAIQ scored 82.4 out of 100, 93 percent of customers said they would buy again and 96 percent confirmed that MOSAIQ is part of their long-term plans.
MOSAIQ is at the heart of Elekta’s software vision: information-guided cancer care. This concept puts patients at the center, guiding the cancer management process. The entire care team is always informed and automated decision support tools, combined with clinical intelligence enable the care team to quickly adapt the patient’s treatment as needed. KLAS research is based on extensive surveys of many healthcare providers.
The Carbon Disclosure Project (CDP) recognized Elekta for its actions to reduce carbon emissions and mitigate the business risks of climate change. Elekta has therefore been awarded a position on The A List: The CDP Climate Performance Leadership Index 2014. The index presents 187 listed companies identified as demonstrating a superior approach to climate change mitigation. It has been produced at the request of 767 investors who represent more than a third of the world’s invested capital by CDP, the international NGO that drives sustainable economies.
The award is presented each year by the Queen on the advice of the prime minister, who is assisted by an Advisory Committee that includes representatives of government, industry and commerce, and the trade unions. The Queen’s Award for International Trade acknowledges Elekta’s third-consecutive year of continuous improvement in the company’s overseas sales. Exports have more than doubled over the last six years.
Leksell Gamma Knife Perfexion, Elekta’s premier intracranial radiosurgery system, took the top rank for the fourth year in a row in KLAS research firm’s 2014 Best in KLAS Awards: Medical & Infrastructure report. In the report, Perfexion scored 94.5 out of 100 on the system’s functionality and upgrade capacity.
As in previous quarterly reports, MD Buyline's Q1 2014 report ranks Elekta highly for key technologies in radiation therapy. Elekta leads the market average in 2-year trend ratings (Q2 2012-Q1 2014) in the categories of oncology information management systems, stereotactic radiosurgery (SRS) systems, remote afterloaders and treatment planning systems (TPS). Vendors are rated on a 1 to 10 scale according to user satisfaction with system performance, system reliability, system installation/implementation, applications training, service response time and service repair quality. Elekta’s ratings: OIS (9.1 v. Varian at 8.5), SRS (8.9), remote afterloader (8.9), TPS (9.0 v. Varian and Philips at 8.9).
MD Buyline has provided healthcare facilities with business intelligence for over 25 years. MD Buyline’s highly respected recommendations on linear accelerators, stereotactic radiosurgery, oncology information systems and treatment planning systems are used by clinicians and senior management to investigate and validate purchasing decisions.
In the 2013 Medtech Value Creators Report, Elekta ranks fifth in a field of 65 medical-equipment manufacturers with a market valuation greater than $1 billion. The report was generated by The Boston Consulting Group, a global management consulting firm and the world’s leading advisor on business strategy. Rankings of medical equipment manufacturers, in addition to medical device companies, medical supply companies and in vitro diagnostics companies were based on the total shareholder return (TSR) percentage.
According to the report, for more than 10 years, the medtech sector has outperformed the overall capital market in terms of financial performance. It has generated a TSR of 279 percent since 2001, substantially beating the MSCI World Index, which returned 98 percent over the same period.
In June 2013, Leksell Gamma Knife Perfexion earned the number one ranking for radiation therapy in the KLAS research firm’s recently released 2013 Best in KLAS Awards: Medical Equipment & Infrastructure report. This is the second consecutive year in which Perfexion has won the Best in KLAS award for radiation therapy.
This was an independent report from healthcare executives and professionals carried out by KLAS, which gathered performance rating over the past 12 months for medical equipment and infrastructure vendors. In the report, Perfexion scored 92.9 out of 100, and 96 percent of customers indicated they would buy again. On a 1 to 9 scale, Perfexion received an 8.7 from respondents for satisfaction with product uptime, the highest score among all vendors rated in the market segment.
The Institute of Physics (IOP) recently named Elekta as one of the companies chosen to receive an IOP Innovation Award for physics innovation in the UK and Ireland. One of five recipients, the company was selected based on the development of its Agility multileaf collimator. The innovative design of Agility, based on physics research and development, utilizes industry-leading technology to provide faster, more accurate and more versatile radiation therapy for individuals with cancer.
How beam shaping technology is improving cancer treatments